MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis
- PMID: 27257145
- PMCID: PMC5065077
- DOI: 10.1530/EJE-16-0461
MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis
Abstract
Objective: Adrenal masses are incidentally discovered in 5% of CT scans. In 2013/2014, 81 million CT examinations were undertaken in the USA and 5 million in the UK. However, uncertainty remains around the optimal imaging approach for diagnosing malignancy. We aimed to review the evidence on the accuracy of imaging tests for differentiating malignant from benign adrenal masses.
Design: A systematic review and meta-analysis was conducted.
Methods: We searched MEDLINE, EMBASE, Cochrane CENTRAL Register of Controlled Trials, Science Citation Index, Conference Proceedings Citation Index, and ZETOC (January 1990 to August 2015). We included studies evaluating the accuracy of CT, MRI, or (18)F-fluoro-deoxyglucose (FDG)-PET compared with an adequate histological or imaging-based follow-up reference standard.
Results: We identified 37 studies suitable for inclusion, after screening 5469 references and 525 full-text articles. Studies evaluated the accuracy of CT (n=16), MRI (n=15), and FDG-PET (n=9) and were generally small and at high or unclear risk of bias. Only 19 studies were eligible for meta-analysis. Limited data suggest that CT density >10HU has high sensitivity for detection of adrenal malignancy in participants with no prior indication for adrenal imaging, that is, masses with ≤10HU are unlikely to be malignant. All other estimates of test performance are based on too small numbers.
Conclusions: Despite their widespread use in routine assessment, there is insufficient evidence for the diagnostic value of individual imaging tests in distinguishing benign from malignant adrenal masses. Future research is urgently needed and should include prospective test validation studies for imaging and novel diagnostic approaches alongside detailed health economics analysis.
© 2016 The authors.
Figures
Similar articles
-
Imaging modalities for characterising focal pancreatic lesions.Cochrane Database Syst Rev. 2017 Apr 17;4(4):CD010213. doi: 10.1002/14651858.CD010213.pub2. Cochrane Database Syst Rev. 2017. PMID: 28415140 Free PMC article.
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article.
-
A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.Health Technol Assess. 2010 Oct;14(50):1-103. doi: 10.3310/hta14500. Health Technol Assess. 2010. PMID: 21044553
-
Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD013362. doi: 10.1002/14651858.CD013362.pub2. Cochrane Database Syst Rev. 2021. PMID: 34611889 Free PMC article.
-
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2. Cochrane Database Syst Rev. 2017. PMID: 29164603 Free PMC article.
Cited by
-
Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass.Can Urol Assoc J. 2023 Feb;17(2):12-24. doi: 10.5489/cuaj.8248. Can Urol Assoc J. 2023. PMID: 36849113 Free PMC article. No abstract available.
-
Approach to the Patient With Adrenal Incidentaloma.J Clin Endocrinol Metab. 2021 Oct 21;106(11):3331-3353. doi: 10.1210/clinem/dgab512. J Clin Endocrinol Metab. 2021. PMID: 34260734 Free PMC article. Review.
-
Adrenocortical carcinoma classified as benign: the limitations of washout values.Endocrinol Diabetes Metab Case Rep. 2025 Apr 24;2025(2):e240022. doi: 10.1530/EDM-24-0022. Print 2025 Apr 1. Endocrinol Diabetes Metab Case Rep. 2025. PMID: 40273001 Free PMC article.
-
Surgical treatment of adrenal tumors during pregnancy.Rev Endocr Metab Disord. 2023 Feb;24(1):107-120. doi: 10.1007/s11154-022-09744-7. Epub 2022 Jul 1. Rev Endocr Metab Disord. 2023. PMID: 35776233 Free PMC article. Review.
-
How to Differentiate Benign from Malignant Adrenocortical Tumors?Cancers (Basel). 2021 Aug 30;13(17):4383. doi: 10.3390/cancers13174383. Cancers (Basel). 2021. PMID: 34503194 Free PMC article. Review.
References
-
- Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation 2006. 29 298–302. (10.1007/BF03344099) - DOI - PubMed
-
- Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumours of the Italian Society of Endocrinology. Journal of Clinical Endocrinology & Metabolism 2000. 85 637–644. (10.1210/jcem.85.2.6372) - DOI - PubMed
-
- OECD. OECD Stat (database). 2015.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials